HLS Therapeutics Inc. (HLS.TO)
HLS Therapeutics Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Etobicoke, ON, CA. The stock last traded at $3.90, up 1.83% on the session, giving a market capitalisation of $122.0M. Its beta of 0.86 implies it has historically moved less than the broad market.
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
HLS Therapeutics Inc. is most often compared with the following Healthcare names: